The prostate health index selectively identifies clinically significant prostate cancer. - Wikidata - awgldk - TriplyDB

The prostate health index selectively identifies clinically significant prostate cancer.

The prostate health index selectively identifies clinically significant prostate cancer.

http://www.wikidata.org/entity/Q35498981

about

Active surveillance for prostate cancer: current evidence and contemporary state of practice Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1.Risk stratification of prostate cancer in the modern era.Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy.Biomarkers for prostate cancer: present challenges and future opportunities.An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.Current biomarkers for diagnosing of prostate cancer.Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience.The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study.The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.Clinical Utility of Biomarkers in Localized Prostate Cancer.The role of prostate cancer biomarkers in undiagnosed men.Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.Prostate Health Index density improves detection of clinically significant prostate cancer.Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies.Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.Who and when should we screen for prostate cancer? Interviews with key opinion leaders.Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia.Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.Prostate biopsy decisions: one-size-fits-all approach with total PSA is out and a multivariable approach with the Prostate Health Index is in.Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.Summary statement on screening for prostate cancer in Europe.Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting.Fascin is secreted in male's serum: results of a pilot study.Prostate Cancer Screening.Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort

P2860

Q28066534-6AD1AA1E-548E-4F58-B4A9-11311380C92B Q28075610-180B0469-ECDD-4E8F-B2B1-6E468B2A6456 Q33668692-53D907B2-3709-4AE2-9E14-7590543C479E Q35680101-2D872AC0-F9F3-4360-9600-323297570A61 Q36238237-3AE112B4-9F29-4364-B74D-CF8D9153ADDB Q36416441-3DF6494C-6804-4FCB-9388-8023D171F611 Q37206050-C0546587-E425-4BD8-B5FD-10B17E954EBD Q37474443-A2BBAFF8-4F8D-48D6-9B52-B42B7DE618A8 Q37691113-CBD00DFE-3460-45D3-B80E-6D93CBBB5D4E Q38584370-017543D6-AF49-4EA5-9F15-33FD146A8542 Q38626590-BF85B058-76A1-4398-932E-6BBADAF58163 Q38684598-63C26C38-FAB2-4A7F-92A3-1492B11F7E62 Q38741968-6E2FA78A-F405-4778-907B-C00F2FF9D135 Q38792354-FE57E9DA-545D-4F2D-8871-FBDB897516F7 Q39140686-79B33846-96FF-4926-9073-66E6CEAC5BE6 Q40140207-3FD64DE4-9B24-4C3E-B8E6-EBCF4B247961 Q40404113-DB21C41B-80BE-4B78-852E-9904061C0DCE Q40412845-79D3440B-2646-438B-95AE-40692A16BFAF Q40433157-0A7938A4-3739-4B0C-93AF-4E4A37E9AA68 Q40438258-92DA55B2-E0F4-4D47-84EB-32CD2EAAEB6A Q40541815-3E4F9528-04EE-4312-9424-7C4DDEFBEEAF Q42231619-99DC7496-89C0-415D-8B82-13FC79660185 Q43152601-47CB0B67-BCD8-4ED0-A839-1C1A69627279 Q43169980-AE87CE8A-C071-4A56-901E-C86DE0894E96 Q47098249-7517F4EB-41A9-4BF0-BEC0-3D743B2FAADC Q47123251-B82EA2AC-66AB-48BD-976A-2240AE55D579 Q47303003-303E92C1-6B8F-4D45-BF8C-4D0E98F2CE81 Q47382349-B0012391-4D72-40ED-92BA-86FFA0E8CA77 Q47436741-E9DB5279-6E66-48CE-98AF-33BB006FE9DB Q47901606-5199B20C-1BE0-42EA-A30A-FF877780FE65 Q49710514-FAC6346F-02BE-4FBD-81D6-A219166FF2E5 Q51781558-542DF687-7709-4CEB-87B7-1B4257BB9E66 Q52641462-98454732-CD5E-43E2-8B0A-BD32F7308F46 Q52698894-BC9012E7-103E-4D5C-B85E-10A50796EE2E Q54986662-BE47E016-B857-4849-9279-BACC7227373B Q57150651-A51F065B-C6C0-48F5-BE4F-99EDA60131C3 Q58799069-2A2F8ACC-88E7-44FC-AD63-BF724D5B8743

P2860

The prostate health index selectively identifies clinically significant prostate cancer.

http://www.wikidata.org/entity/Q35498981

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The prostate health index selectively identifies clinically significant prostate cancer.

@ast

The prostate health index selectively identifies clinically significant prostate cancer.

@en

type

label

The prostate health index selectively identifies clinically significant prostate cancer.

@ast

The prostate health index selectively identifies clinically significant prostate cancer.

@en

prefLabel

The prostate health index selectively identifies clinically significant prostate cancer.

@ast

The prostate health index selectively identifies clinically significant prostate cancer.

@en

P1433

Q35498981-F3A87A29-55F1-4C92-84EF-36415B8ABFCE

P1476

Q35498981-6D30F18B-3A24-4478-AF0D-694174132B60

P2093

Q35498981-0B28C100-B9C9-4C6C-A4F0-5872DAC5913B

Q35498981-301F7616-EF7A-47AC-BA51-FC84AE114DB4

Q35498981-39D8CC53-8A11-4AFA-AD93-9B2CA557048D

Q35498981-488FBF5F-27DC-4A7A-A537-3167478E41BE

Q35498981-51589BF0-E3F1-427B-B411-E8E28CF5A6BC

Q35498981-5F9C0B4A-132B-4F82-A1BB-3597C70DA86D

Q35498981-61DAECEE-BFAC-43C7-A063-56074F68B310

Q35498981-7E76D036-BE1F-4177-8567-9951D7DECABF

Q35498981-876ABF54-67F1-4AB5-9844-E038AADB7079

Q35498981-8E02AC52-2AFE-4707-BB11-162AFEB3E1BA

P2860

Q35498981-01BC67EA-0E6B-42D6-98CB-F7E95EEE1140

Q35498981-198BB467-B029-4B57-9FD1-0CA8212C90A5

Q35498981-27C72CA8-41CF-4C46-BDE2-4C766AC124D1

Q35498981-29CA8CF8-1F08-4EA8-A36F-99DC2A68379D

Q35498981-3FB37312-D805-457F-96DA-1A7BAF2FDAF3

Q35498981-3FBBC4B8-D3FB-4BA1-A64E-B117CA8159C0

Q35498981-41878F53-03F3-4618-965D-FAE0A95EF7E8

Q35498981-4DA0FA66-836C-4E6E-8BEB-709C98BF6354

Q35498981-52AAB570-FE66-4CA6-8E9C-68A92ECE34C2

Q35498981-52F8E9E5-60E6-4FF1-B9F2-2D1713FA9B53

P304

Q35498981-027E25B9-81A0-42D0-BF5A-F9847BE537D5

P31

Q35498981-8A5123E8-5D65-4CE3-978B-FDA49FB65718

P356

Q35498981-CE791FD2-B9A3-4AA5-ADDB-848E550364D4

P407

Q35498981-8E50859D-2080-4EEE-B681-A8E1F9BF05BB

P433

Q35498981-1281D568-FD65-4452-9272-C0CB8E1234B2

P478

Q35498981-62AE4B2B-F736-4D44-87AB-B4F2949D9503

P50

Q35498981-22BEB9A5-B186-4359-AC77-6A10F9FE2865

P577

Q35498981-B4FD7324-3ECB-46B4-BFF4-779057369499

P698

Q35498981-8202F061-1756-4F5C-B757-E7FFE9B615F9

P932

Q35498981-37E32BA9-8202-4353-A2BC-538585AD385E

P356

J.JURO.2014.10.121

P1433

The Journal of Urology

P1476

The prostate health index selectively identifies clinically significant prostate cancer.

@en

P2093

Amabelle B Cruz

http://www.w3.org/2001/XMLSchema#string

Chris H Bangma

http://www.w3.org/2001/XMLSchema#string

Daniel W Chan

http://www.w3.org/2001/XMLSchema#string

Dennis L Broyles

http://www.w3.org/2001/XMLSchema#string

George G Klee

http://www.w3.org/2001/XMLSchema#string

Isaac A Mizrahi

http://www.w3.org/2001/XMLSchema#string

John T Wei

http://www.w3.org/2001/XMLSchema#string

Kevin M Slawin

http://www.w3.org/2001/XMLSchema#string

Leonard S Marks

http://www.w3.org/2001/XMLSchema#string

Lori J Sokoll

http://www.w3.org/2001/XMLSchema#string

P2860

Overdiagnosis and overtreatment of prostate cancer

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Prostate-cancer mortality at 11 years of follow-up.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

P304

1163-1169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2014.10.121

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

193

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25463993

http://www.w3.org/2001/XMLSchema#string

P932

4404198

http://www.w3.org/2001/XMLSchema#string